Table 3.
Summary of study characteristics.
| Reference | Country | n | Condition | Gender | Age a | BMI a | Year Collection | Adipose Tissue | Serum | Ratio c | Meta d | Dioxin | PCB | OCP | BFR | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (Years) | (kg/m2) | Fasting | Units | |||||||||||||
| [52] | France | 86 | Caesarean | F | 33 (20–46) | NA | 2004–2006 | SAT | Yes | LW | 25 | |||||
| [35] | Spain | 103 | NA | F | 54 (SD:12) | 27 | 2012–2014 | BAT | Yes | WW | X | 3 | 2 | |||
| [35] | Spain | 103 | NA | F | 54 (SD:12) | 27 | 2012–2014 | BAT | Yes | LW | X | X | 3 | 2 | ||
| [51] | Bolivia | 112 | NA | M/F+ | 31 (18–70) | 27 | 2010 | VAT | NA | WW | X | 3 | 3 | |||
| [51] | Bolivia | 112 | NA | M/F+ | 31 (18–70) | 27 | 2010 | VAT | NA | LW | X | X | 3 | 3 | ||
| [53] | Spain | 387 | NA | M/F | 52 b (37–63) | 27 | 2003–2004 | SAT | No | LW | 1 | |||||
| [54] | Italy | 70 | Caesarean | F | 33 b (SD:4) | 24 | 2006 | SAT | NA | LW | 30 | 3 | ||||
| [55] | Sweden | 20 | Stillbirths | F | 25–40 | 21–35 | 2015–2016 | FAT | NA | WW | X | 10 | 9 | 3 | ||
| [50] | Qatar | 34 | IR | M/F | 32 b (SD: 10) | 45 | NA | SAT, VAT | No blood | 28 | ||||||
| [48] | France | 42 | Obesity/H | M/F | 44/40 | 48/22 | 2006–2008 | SAT(VAT) | NA | W/LW | 17 | 18 | ||||
| [56] | Korea | 50 | T2D/N-T2D | M/F | 66/62 (8/11) | 23 (3) | NA | SAT,VAT | No blood | 19 | 13 | |||||
| [10] | France | 48 | BC | F | 64 | 24 | 2015 | BAT | No | LW | X | X | 18 | 8 | ||
| [36] | China | 37–55 | Caesarean | F | 29 | 21 | 2011 | SAT | Yes | LW | X | X | 6 | 8 | ||
| [36] | China | 37–55 | Caesarean | F | 29 | 21 | 2011 | SAT | Yes | WW | X | 6 | 8 | |||
| [43] | Mexico | 198 | BC/H | F | 40 (19–78) | NA | 1994–1996 | BAT | No | LW | 1 | |||||
| [49] | Belgium | 52 | Obesity | M/F | 40 (18–58) | 42 | 2010–2012 | SAT, VAT | No blood | 28 | 2 | |||||
| [57] | Belgium | 101 | Infertile | F | 32 (24–42) | 1996–1998 | SAT | LW | 7 | 7 | ||||||
| [58] | Portugal | 189 | Obesity | M/F+ | 43 (19–65) | 45 (5) | 2010–2011 | SAT, VAT | No blood | 1 | 11 | |||||
| [46] | France | 67 | ENDO/H | M+/F | 34 (48–80) | 24 | 2013–2015 | VAT, SAT | NA | LW | X | X | 18 | 8 | ||
| [47] | US | 473 | ENDO/H | F | 33 (IQR:11) | 26(IQR:10) | 2007–2009 | VAT | No | WW | X | 13 | 5 | 5 | ||
| [59] | India | 29 | BC | F | 24–65 | NA | 1996–1997 | BAT | Yes | WW | X | 2 | 3 | |||
| [59] | India | 29 | BC | F | 24–65 | NA | 1996–1997 | GAT | Yes | WW | X | 2 | 3 | |||
| [59] | India | 29 | BC | F | 24–65 | NA | 1996–1997 | BAT | Yes | LW | X | 2 | 3 | |||
| [59] | India | 29 | BC | F | 24–65 | NA | 1996–1997 | GAT | Yes | LW | X | 2 | 3 | |||
| [44] | Australia | 32 | NA | M/F | 55 (22–89) | 25 | 2016 | SAT | Yes | LW | X | 3 | ||||
| [45] | Italy | 59 | HCC | M+/F | 69 (48–80) | NA | NA | VAT | Yes | LW | X | X | 7 | |||
a Mean age or body mass index and range, standard deviation (SD) or interquartile range (IQR), b geometric mean or median, c identifier of studies that reported ratios, d identifier of studies included in the meta-regression. Abbreviations: BAT, breast adipose tissue; BC, breast cancer; BFR, brominated flame retardants; BMI, body mass index; FAT, fetal adipose tissue; GAT, gluteal adipose tissue; F, female; F+, overrepresentation of female; H, healthy subjects; HCC, hepatocellular carcinoma; IQR, interquartile range; IR, insulin resistance; LW, lipid weight; M, male; NA, not available; OCP, organochlorinated pesticides; PCBs, polychlorinated biphenyls; R, identifier for studies reporting calculated partition ratios; SAT, subcutaneous adipose tissue; SD, standard deviation; VAT, visceral adipose tissue; WW, wet weight.